Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chugai Pharmaceutical has signed a licensing deal with F Hoffmann-La Roche for humanized anti-Met antibody MetMAb and humanized anti-interleukin(IL)-13 antibody lebrikizumab.
Subscribe to our email newsletter
Currently under development using the personalized healthcare (PHC) approach by Roche, MetMAb is indicated as a treatment for non-small cell lung cancer (NSCLC) and lebrikizumab for bronchial asthma.
The tie up allows Chugai to develop and market these compounds in Japan.
As per the terms of the agreement, Roche is eligible to receive milestone payments from Chugai.